Literature DB >> 17014897

Thromboembolic complications in patients with clear cell carcinoma of the ovary.

Yusuke Matsuura1, Greg Robertson, Donald E Marsden, Soo-Nyung Kim, Val Gebski, Neville F Hacker.   

Abstract

OBJECTIVE: The purpose of this study was to define the incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients with clear cell carcinoma (CCC) of the ovary and to investigate the prognostic factors in such patients.
METHODS: Between January 1987 and December 2003, 641 women with primary invasive epithelial ovarian cancer underwent treatment at the Royal Hospital for Women in Sydney, Australia. Sixty-six patients (10.3%) with CCC were identified from the data bank, and their data were compared with a matched-control group of 132 patients with non-clear cell epithelial ovarian carcinoma.
RESULTS: A thromboembolic event (DVT or PE) was noted in 27.3% of patients with CCC, compared to 6.8% of patients with other epithelial ovarian cancers. PE was detected in 13.6% and 3.8% of patients, respectively. In patients with CCC, DVT was frequently observed before operation or at the time of recurrence. In a multivariate analysis of patients matched for age and stage, the occurrence of a DVT or the presence of endometriosis was significant predictors of clear cell histology. Within the clear cell group, no particular risk factor for DVT could be identified. Metastases of 50 mm or greater in diameter, ascites of 1000 ml or more, advanced FIGO stage, and the occurrence of DVT were poor prognostic factors for CCC in univariate analysis, but in a multivariate Cox regression analysis, only FIGO stage and occurrence of DVT remained significant.
CONCLUSION: The incidence of venous thromboembolic events was found to be significantly higher in patients with CCC when compared to patients with other epithelial ovarian cancers.

Entities:  

Mesh:

Year:  2006        PMID: 17014897     DOI: 10.1016/j.ygyno.2006.08.026

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  18 in total

1.  Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.

Authors:  Alice Chanakira; Pamela R Westmark; Irene M Ong; John P Sheehan
Journal:  Gynecol Oncol       Date:  2017-01-29       Impact factor: 5.482

Review 2.  Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.

Authors:  Kazuaki Takahashi; Masataka Takenaka; Ayako Kawabata; Nozomu Yanaihara; Aikou Okamoto
Journal:  Int J Clin Oncol       Date:  2020-01-27       Impact factor: 3.402

3.  Clear cell carcinoma of the ovary associated with increased risk of venous thrombosis.

Authors:  Varsha Podduturi; Joseph M Guileyardo
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-10

4.  Synchronous primary corpus and ovarian cancer: High incidence of endometriosis and thrombosis.

Authors:  Koji Yamanoi; Masaki Mandai; Ayako Suzuki; Noriomi Matsumura; Tsukasa Baba; Yumiko Yoshioka; Kenzo Kosaka; Ikuo Konishi
Journal:  Oncol Lett       Date:  2012-06-22       Impact factor: 2.967

5.  Optimal cytoreductive surgery for underlying ovarian cancer associated with deep venous thrombosis without placement of inferior vena cava filter: A case report and literature review.

Authors:  Hongwei Shen; Jianhong Shang; Gang Niu; Jun Liu; Zeshan You; Shanyang He
Journal:  Oncol Lett       Date:  2015-07-15       Impact factor: 2.967

6.  Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma.

Authors:  Kazuki Takasaki; Morikazu Miyamoto; Masashi Takano; Hiroaki Soyama; Tadashi Aoyama; Hiroko Matsuura; Hideki Iwahashi; Hiroki Ishibashi; Takahiro Sakamoto; Kenichi Furuya
Journal:  Int J Clin Oncol       Date:  2019-05-09       Impact factor: 3.402

7.  Tissue factor pathway inhibitor 2 as a serum marker for diagnosing asymptomatic venous thromboembolism in patients with epithelial ovarian cancer and positive D-dimer results.

Authors:  Ryuta Miyake; Yuki Yamada; Shoichiro Yamanaka; Ryuji Kawaguchi; Norihisa Ootake; Shohei Myoba; Hiroshi Kobayashi
Journal:  Mol Clin Oncol       Date:  2021-12-23

8.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Authors:  Ankur K Nagaraja; Chad J Creighton; Zhifeng Yu; Huifeng Zhu; Preethi H Gunaratne; Jeffrey G Reid; Emuejevoke Olokpa; Hiroaki Itamochi; Naoto T Ueno; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2010-01-15

9.  Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.

Authors:  Koji Matsuo; Kosei Hasegawa; Kiyoshi Yoshino; Ryusuke Murakami; Takeshi Hisamatsu; Rebecca L Stone; Rebecca A Previs; Jean M Hansen; Yuji Ikeda; Akiko Miyara; Kosuke Hiramatsu; Takayuki Enomoto; Keiichi Fujiwara; Noriomi Matsumura; Ikuo Konishi; Lynda D Roman; Hani Gabra; Christina Fotopoulou; Anil K Sood
Journal:  Eur J Cancer       Date:  2015-07-31       Impact factor: 9.162

10.  Effect of ovarian tumor characteristics on venous thromboembolic risk.

Authors:  Arvind Bakhru
Journal:  J Gynecol Oncol       Date:  2013-01-08       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.